Nature Reviews Gastroenterology & Hepatology

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	800
Zolbetuximab treatment in metastatic gastric cancer	547
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	532
Hybrid EASL Congress 2023	520
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	474
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	454
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	419
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	394
Mapping neuroimmune interactions in the gut	373
Digestive Disease Week 2022	356
Nomenclature of HBV core protein-targeting antivirals	340
Black–White disparities across the colorectal cancer care continuum in the USA	319
Western lifestyle, metaflammation and the cell of origin of colon cancer	255
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	249
2023 FDA approvals in gastroenterology and hepatology	246
Large language models for clinical decision support in gastroenterology and hepatology	242
Advancing nutrition science for global health	230
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	228
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	206
Artificial intelligence and automation in endoscopy and surgery	205
Oral microbiome therapy efficacious for recurrent C. difficile infection	202
Wound healing in the colon	195
Hepatic IRF3 in glucose intolerance	193
New understanding of hepatobiliary MRI	185
Decoding therapy resistance in liver tumours: a giant leap	183

GWAS reveals variants for alcohol-related hepatocellular carcinoma	183
Metastatic pancreatic cancer and the liver	183
Lessons from incretin-based therapy in MASH and obesity	173
A crucial Fusobacterium nucleatum clade in colorectal cancer	170
Food as medicine in gastrointestinal cancer therapy	166
Inflammatory bowel disease in pregnancy and breastfeeding	161
The global burden of coeliac disease: opportunities and challenges	157
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	156
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	142
Bacteriophages and their potential for treatment of gastrointestinal diseases	141
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	137
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	136
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	135
Integrated systems approach to identify environmental factors in intestinal inflammation	128
HDCA ameliorates NAFLD in mice	128
Preventing the progression of cirrhosis to decompensation and death	127
Metabolic diseases in the East Asian populations	127
Characterizing the genomic landscape of colorectal cancer	124
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease	124
Implications of the evolving knowledge of the genetic architecture of MASLD	124
Lanifibranor and NASH resolution	123
Estimating dietary intake from human stool DNA	119
The path to successful hepatitis C elimination in Spain	118
Probiotics for preterms: sharing complex decision-making	117
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment	109
Proteases in intestinal health and disease	105
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	105
SSRIs and depression: role of gut–brain communication	104
Medical therapy of paediatric inflammatory bowel disease	103
Liver, ageing and disease	101
Current and future colorectal cancer screening strategies	100
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	99
Human intestinal B cells in inflammatory diseases	99
NAFLD prevalence in older patients with T2DM	97
Phase III results for first-line treatment for metastatic colorectal cancer	96
Author Correction: Hepatic immune regulation and sex disparities	92
ECCO’24	91
The future of pathology in gastroenterology and hepatology	89
Microbiota and colorectal cancer — controlling for confounders challenges associations	88
GLP1R agonists in NAFLD: a promising therapy on the horizon	86
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	83
Enteric nervous system transfers stress to the gut	81
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	80
Gut microbiome and autism spectrum disorder	79
Transforming the landscape of liver cancer detection and care	79
Hepatic glucose metabolism in the steatotic liver	78
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	75
Artificial intelligence in liver cancer — new tools for research and patient management	75
Foundations of gastrointestinal-based drug delivery and future developments	70
Hepatic inflammatory responses in liver fibrosis	68

SMART cancer risk prediction	66
Immunoregulatory role of enteric glia	65
Liver dialysis in ACLF	62
Elucidating the transmission landscape of the human microbiome	60
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel	57
Hepatitis E virus: from innate sensing to adaptive immune responses	57
AI predicts pancreatic cancer risk	57
Gut bacteria go on record	55
International collaborative research to improve gallbladder cancer prevention	54
A neurobiotic sense curbs feeding: a new frontier in gut–brain communication	54
A new era in obesity management	54
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	50
Nutrient sensing and small intestinal enteric neurons	49
Nifty new tools for microbiome treatment design	46
MASLD as a non-communicable disease	45
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	44
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	44
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	44
Tirzepatide to treat obesity: phase III results	43
Cathepsin S in liver fibrogenesis	43
A novel pathomics signature for gastric cancer	41
Origin of CAFs in colorectal cancer	40
Commensal fungi in intestinal health and disease	39
Bridging the gap: increasing MENA representation in MASLD clinical trials	37
The steatotic liver disease burden paradox: unravelling the key role of alcohol	37
Natural history of NAFLD: knowns and unknowns	35
Cellular and molecular basis of proximal small intestine disorders	35
Classifying compounds as prebiotics — scientific perspectives and recommendations	34
Therapeutic landscape and future direction of metastatic colorectal cancer	34
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	34
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	33
Antibiotic-perturbed microbiota and the role of probiotics	33
Danger! P2Y14 receptor links cell death to liver fibrosis	32
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	32
Author Correction: Improving IBD outcomes in the era of many treatment options	31
Long-term normothermic liver perfusion	31
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	30
Justice, equity, diversity and inclusion in gastroenterology and hepatology	29
Alcohol-free and low-strength drinks: friend or foe?	29
Diet-driven microbiome restoration associated with cardiometabolic benefits	28
Hippo signalling in the liver: role in development, regeneration and disease	28
Author Correction: Current and future colorectal cancer screening strategies	28
A Roadmap for the Human Gut Cell Atlas	27
Changes in cholera burden across Africa	26
Global epidemiology of cirrhosis — aetiology, trends and predictions	25
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	25
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	25
Defining the mucosal ecosystem: epithelial–mesenchymal interdependence in gastrointestinal health and disease	25
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	25
Public health policies to prevent alcohol-related liver disease	25
Resmetirom safe for nonalcoholic fatty liver disease	24
New target and timing in PDAC immunotherapy?	24
Digestive Disease Week 2023	23
ECCO’25	23
Deciphering potential implications of dietary microplastics for human health	23
Elafibranor in primary biliary cholangitis	23
A resource for the food microbiome and its links with the human microbiome	22
Location, location, location — spatial insight into hepatic macrophage populations	22
Digestive Disease Week 2025	22
Intermittent fasting for NASH and HCC in mice	22
Food inequity and insecurity and MASLD: burden, challenges, and interventions	22
Positive longer-term results for efruxifermin in MASH	22
Tissue-resident memory CD8+ T cells: master deciphers of the hepatic environment	22
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	21
HCV direct-acting antiviral therapy adherence in people who inject drugs	21
Envisioning how to advance the MASH field	21
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	21
Nanoparticles in NAFLD therapeutics	20
Human liver tissue in a mouse host	20
Follow-up of SER-109 for recurrent C. difficile	20
Gastrointestinal health and the environment: a bidirectional relationship	19
Amitriptyline as second-line treatment for IBS in primary care settings	18
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	17
COVID-19 and liver disease: where are we now?	17
IL-17A-producing CD8+ T cells in pancreatic cancer	17
Gastrointestinal post-acute COVID-19 syndrome	16
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	16
Lactylation and HCC progression	16
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	15
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	15

Liver steatosis and fibrosis in China	14
Elucidating the link between clonal haematopoiesis and chronic liver disease	14
Mapping the malignant transformation from polyps to CRC	14
Positioning therapies for the management of inflammatory bowel disease	13
Combination treatment further extends survival	13
Maintaining remission in ulcerative colitis	13
Mucus secretion from colonic goblet cells is regulated by autophagy and ER stress	13
Elucidating the nutrient preferences of mouse gut bacteria	13
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD	12
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards	12
Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	12
‘Dark matter’ beyond the bacteria in faecal microbiota transplantation	12
Neoadjuvant chemotherapy for operable colon cancer	12
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions	12
Secretory IgA: controlling the gut microbiota	12
Actions of thyroid hormones and thyromimetics on the liver	11
Fermented foods and gastrointestinal health: underlying mechanisms	11
Host–pathobiont interactions in Crohn’s disease	11
Paracellular permeability and tight junction regulation in gut health and disease	11
Biologic agents for IBD come of age as host–microbe interactions emerge	11
Liquid biopsy guides anti-EGFR rechallenge in metastatic CRC	10
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	10
Liver transplantation plus chemotherapy improved survival in patients with colorectal liver metastasis	10
Redefining cancer care: the case for an onco-gastroenterology subspecialty	10
Cellular triads in T cell liver tumours	10
A bloody disgrace — time to change patient safety culture	10
Rethinking gastric cancer prevention through an immigrant health lens	9
Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy	9
Sex bias in clinical trials in gastroenterology and hepatology	9
Next-generation enteric neuroscience — fostering the future of the field	9
The war on pancreatic cancer: progress and promise	9
Precision models in hepatocellular carcinoma	8
Diversity, development and immunoregulation of enteric neurons	8
An expert panel Consensus Statement on ALD without experts by experience	8
Mechanisms of metastatic colorectal cancer	8
Anatomy-preserving adjustable intragastric balloon is safe and promotes durable weight loss	8
Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease	8
IgG4-related diseases of the digestive tract	8
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity	8
Liraglutide treatment in children with obesity	8
CXCR2 inhibition in NASH-HCC	7
Stigma: a major barrier to hepatitis B elimination	7
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?	7
The appendix and ulcerative colitis — an unsolved connection	7
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders	7
Understanding the therapeutic toolkit for inflammatory bowel disease	7
Connecting with the community	7
NAFLD, MAFLD and obesity: brothers in arms?	7
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction	7
Human hepatocyte organoids model early NAFLD	6
Metabolic health across the ages: how microbiota members support our well-being	6
Contrasting aspects of human excreta	6
Rhythmicity of infant microbiota and dietary effects	6
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	6
Pouchitis: pathophysiology and management	6
Crosstalk between enteric neurons and colorectal cancer stem cells influences self-renewal	6
Effect of bariatric surgery on risk of oesophagogastric cancer	6
WNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials	6
Beyond preservation: future machine perfusion for liver assessment and repair	5
Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	5
Hepatitis C testing, treatment and prevention in low- and middle-income country prisons	5
Mechanisms and pathophysiology of Barrett oesophagus	5
Liver fibrosis with methotrexate — an overestimated risk?	5
Novel interventions against alcohol-related liver disease	5
Benign liver tumours: understanding molecular physiology to adapt clinical management	5
Fetal liver development and implications for liver disease pathogenesis	5
Colonoscopy screening and risk of CRC	5
Safety of in utero exposure to maternal IBD pharmacotherapies	5
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	5
Metastasis and pericytes in oesophageal cancer	5
The immune microenvironment in gastric adenocarcinoma	5
Machine perfusion of the liver: applications in transplantation and beyond	5
Combination therapy with methotrexate in paediatric Crohn’s disease	5
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape	5
Advances in liver and pancreas organoids: how far we have come and where we go next	5
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	5
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	4
Women in endoscopy: leading the way	4
Embracing many rainbows: the realities of being a gay physician, mother and patient	4
CIDEB variants protect against liver disease	4
Fazirsiran shows promise for liver disease in AAT	4
Investigating two versus three doses of mRNA vaccine in patients with cirrhosis	4
Upadacitinib therapy for Crohn’s disease	4
Gut feelings: mechanosensing in the gastrointestinal tract	4
Development of MKK4 inhibitors for liver regeneration	4
A link to the past	4
Ultra-processed diet increases CRC risk	4
Therapeutic developments in pancreatic cancer	3
Mechanosensitive release of 5-HT from specialized intestinal epithelial cells	3
Reduction in colorectal cancer incidence by screening endoscopy	3
Bulevirtide for chronic hepatitis D: phase III data	3
Author Correction: Classifying compounds as prebiotics — scientific perspectives and recommendations	3
The metabolic nature of inflammatory bowel diseases	3
Multi-omic links between gut microbiome and cardiovascular disease	3
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies	3